Sign in
Enrolling by invitationNo phase

Natural History Study of SCID Disorders

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Ann Arbor, Atlanta, Bethesda, Birmingham, Boston, Chicago, Cincinnati, Cleveland, Columbus, Dallas, Denver, Durham, Hackensack, Houston, Los Angeles, Madison, Memphis, Milwaukee, Minneapolis, New Orleans, New York, Palo Alto, Philadelphia, Phoenix, Pittsburgh, Portland, Rochester, Salt Lake City, San Antonio, San Francisco, Seattle, St Louis, St. Petersburg, Valhalla, Washington D.C., and Wilmington, United StatesSee the 39 sitesAlso in 1 other country, 5 sites
Trial code
Status
Enrolling by invitation
People taking part
690 people, planned
Started
2 Sept 2010
Expected to end
Sept 2028
Type of study
Observational, 3 groups
Record updated
10 November 2020

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Stratum A: Typical SCID (formerly referred to as Classic SCID)- -Subjects who meet the following inclusion criteria and the intention is to treat with allogeneic hematopoietic cell transplant (HCT) are eligible for enrollment into Stratum A (Typical SCID) of the study:
  • Absence or very low number of T cells (CD3 T cells <300/microliter) AND
  • No or very low T cell function (<10% of lower limit of normal) as measured by response to phytohemagglutinin (PHA) OR
  • T cells of maternal origin present; Stratum B: Leaky SCID, Omenn Syndrome, Reticular Dysgenesis-; -Subjects who meet the following criteria and the intention is to treat with HCT are eligible for enrollment into Stratum B:; Leaky SCID:
  • Maternal lymphocytes tested for and not detected AND
  • Either one or both of the following (a,b) :; a.) <50% of lower limit of normal T cell function as measured by response to PHA, OR response to anti-CD3/CD28 antibody; b.) Absent or <30% of lower limit of normal proliferative responses to candida and tetanus toxoid antigens
  • AND at least two of the following (a through e):; a.) Reduced number of CD3 T cells; age ≤2 years: <1500/microliter; age >2 years and ≤4 years: <800/microliter; age >4 years: <600/microliter; b.) ≥80% of CD3+ or CD4+ T cells that are CD45RO+; AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative; AND/OR >50% of CD3+ or CD4+T cells express HLA-DR (at <4 years of age); AND/OR are oligoclonal T cells; c.) Hypomorphic mutation in IL2RG in a male, or homozygous hypomorphic mutation or compound heterozygosity with ≥1 hypomorphic mutation in an autosomal SCID-causing gene; d.) Low T Cell Receptor Excision Circles (TRECs) and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower limit of normal; e.) Functional testing in vitro supporting impaired, but not absent, activity of the mutant protein, AND
  • Does not meet criteria for Omenn Syndrome; Omenn Syndrome:
  • Generalized skin rash
  • Maternal lymphocytes tested for and not detected; --Note: If maternal engraftment was not assessed and ruled out, the subject is not eligible as Omenn Syndrome
  • ≥80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR; 80% of CD3+ or CD4+T cells are CD62L negative AND/OR; 50% of CD3+ or CD4+ T cells express HLA-DR (at <2 years of age)
  • Absent or low (< 30% lower limit of normal) T cell proliferation response to antigens (Candida, tetanus) to which the subject has been exposed; NOTE: If proliferation to antigen was not performed, but at least 4 of the following 9 supportive criteria, at least one of which must be among those marked with an asterisk (*) below are present, the subject is eligible as Omenn Syndrome:
  • Hepatomegaly
  • Splenomegaly
  • Lymphadenopathy
  • Elevated IgE
  • Elevated absolute eosinophil count
  • *Oligoclonal T cells measured by CDR3 length or flow cytometry
  • *Proliferation to PHA is reduced <50% of lower limit of normal or SI <30
  • *Hypomorphic mutation in a SCID causing gene
  • Low TRECS and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower limit of normal; Reticular Dysgenesis:
  • Absence or very low number of T cells (CD3 <300/µL
  • No or very low (<10% lower limit of normal) T cell response to PHA
  • Severe neutropenia (absolute neutrophil count < 200 /µL) AND
  • ≥2 of the following (a,b,c):; a.) Sensori-neural deafness; b.) Deficiency of marrow granulopoiesis on bone marrow examination; c.) A pathogenic mutation in the adenylate kinase 2 (AK2) gene identified; Stratum C:; Subjects who meet the following criteria and the intention is to treat with therapy other than allogeneic HCT, primarily PEG-ADA ERT or gene therapy with autologous modified (gene transduced) cells, are eligible for enrollment into; Stratum C:
  • ADA Deficient SCID with intention to treat with PEG-ADA ERT
  • ADA Deficient SCID with intention to treat with gene therapy
  • X-linked SCID with intention to treat with gene therapy
  • Any SCID patient previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)
  • Any SCID patient who received therapy for SCID deemed "non-standard" or "investigational", including in utero procedures

Who cannot take part

  • Presence of an Human Immunodeficiency Virus (HIV) infection (by PCR) or other cause of secondary immunodeficiency
  • Presence of DiGeorge syndrome
  • Metabolic conditions that imitate SCID or related disorders such as folate transporter deficiency, severe zinc deficiency or transcobalamin deficiency
  • -Subjects who meet any of the following exclusion criteria are disqualified from enrollment in Strata A, B, or C of the study:
  • MHC Class I and MHC Class II antigen deficiency, and

Where in United States

Also in 1 other country, 5 sites

  • University of Michigan Health SystemAnn Arbor, United StatesEnrolling by invitation
  • Children's Healthcare of Atlanta/Emory University School of MedicineAtlanta, United StatesEnrolling by invitation
  • NIH Clinical Center Genetic Immunotherapy SectionBethesda, United StatesEnrolling by invitation
  • University of Alabama at BirminghamBirmingham, United StatesEnrolling by invitation
  • Children's Hospital, BostonBoston, United StatesEnrolling by invitation
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesEnrolling by invitation
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesEnrolling by invitation
  • University Hospitals Rainbow Babies and Children's HospitalCleveland, United StatesEnrolling by invitation
  • Nationwide Children's HospitalColumbus, United StatesEnrolling by invitation
  • University of Texas Southwestern Medical Center/Children's of DallasDallas, United StatesEnrolling by invitation
  • Children's Hospital DenverDenver, United StatesEnrolling by invitation
  • Duke UniversityDurham, United StatesEnrolling by invitation
  • Hackensack University Medical CenterHackensack, United StatesEnrolling by invitation
  • Texas Children's HospitalHouston, United StatesEnrolling by invitation
  • Children's Hospital Los AngelesLos Angeles, United StatesEnrolling by invitation
  • University of California, Los AngelesLos Angeles, United StatesEnrolling by invitation
  • University of Wisconsin-American Family Children's HospitalMadison, United StatesEnrolling by invitation
  • St. Jude Children's Research HospitalMemphis, United StatesEnrolling by invitation
  • Medical College of WisconsinMilwaukee, United StatesEnrolling by invitation
  • University of Minnesota Medical CenterMinneapolis, United StatesEnrolling by invitation
  • Children's Hospital/Louisiana State University Health Sciences CenterNew Orleans, United StatesEnrolling by invitation
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesEnrolling by invitation
  • Lucile Salter Packard Children's Hospital at StanfordPalo Alto, United StatesEnrolling by invitation
  • The Children's Hospital Of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
  • Phoenix Children s HospitalPhoenix, United StatesEnrolling by invitation
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesEnrolling by invitation
  • Oregon Health and Science UniversityPortland, United StatesEnrolling by invitation
  • Mayo Clinic HospitalRochester, United StatesEnrolling by invitation
  • University of Rochester Medical Center/ Golisano Children's HospitalRochester, United StatesEnrolling by invitation
  • Primary Children's Medical Center/University of UtahSalt Lake City, United StatesEnrolling by invitation
  • Methodist Children's Hospital of South Texas/Texas Transplant InstituteSan Antonio, United StatesEnrolling by invitation
  • University of California San Francisco Children's HospitalSan Francisco, United StatesEnrolling by invitation
  • Seattle Children's Research InstituteSeattle, United StatesEnrolling by invitation
  • Cardinal Glennon Children's Medical CenterSt Louis, United StatesEnrolling by invitation
  • Washington University/St. Louis Children's HospitalSt Louis, United StatesEnrolling by invitation
  • Johns Hopkins All Children's HospitalSt. Petersburg, United StatesEnrolling by invitation
  • New York Medical College, Maria Fareri Children's HospitalValhalla, United StatesEnrolling by invitation
  • Children's National Medical CenterWashington D.C., United StatesEnrolling by invitation
  • Alfred I. duPont Hospital for Children/NemoursWilmington, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This study is a prospective evaluation of children with Severe Combined Immune Deficiency (SCID) who are treated under a variety of protocols used by participating institutions. In order to determine the patient, recipient and transplant-related variables that are most important in determining outcome, study investigators will uniformly collect pre-, post- and peri-transplant (or other treatment) information on all children enrolled into this study.

Read full original descriptionShow less

Children will be divided into three strata:

* Stratum A: Typical SCID with virtual absence of autologous T cells and poor T cell function * Stratum B: Atypical SCID (leaky SCID, Omenn syndrome and reticular dysgenesis with limited T cell diversity or number and reduced function), and * Stratum C: ADA deficient SCID and XSCID patients receiving alternative therapy including PEG-ADA ERT or gene therapy.

Each Group/Cohort Stratum will be analyzed separately.

The 3 groups in the trial

  • Stratum A: Typical SCID +HCT

    Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy. Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol.

  • Stratum B: Atypical SCID +HCT

    Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy. Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol.

  • Stratum C:SCID +Non-HCT

    Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes: * Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) * ADA Deficient SCID with intention to treat with gene therapy * X-linked SCID (XSCID) with intention to treat with gene therapy * Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901)
Publications
Record updated
10 November 2020